On April 27, 2026, Ligand Pharmaceuticals Inc. announced a merger agreement with XOMA Royalty Corporation, where each share of XOMA will be converted to $39.00 in cash plus contingent value rights. This significant event aims to enhance Ligand's operations as the merger proceeds under specific conditions.